Keyword: Fasenra

In the asthma biologics race, there doesn't appear to be a clear favorite among Xolair, Dupixent, Fasenra and Nucala for a group of pulmonologists.

After showing Nucala could cut the rates of flares for hypereosinophilic syndrome, GSK is planning regulatory filings in 2020.

In its severe asthma fight with AstraZeneca’s Fasenra, GlaxoSmithKline could take solace that its drug was more convenient for patients. Not anymore.

Hoping to revive the case, AstraZeneca said it will submit results from another phase 3 trial that weren't originally included in its application.

GlaxoSmithKline's Nucala has been on the prowl for a leg up in severe asthma. Could new real-world data work some magic for the drug?

AstraZeneca and GlaxoSmithKline have locked horns in their battle for respiratory supremacy. Could a trial win and an FDA nod help give AZ a leg up?

GlaxoSmithKline’s Nucala has suffered against a more convenient AstraZeneca rival, but the company finally has an answer.

Facing stiff competition in asthma, Novartis’ Xolair can use all the help it can get to keep its blockbuster status. Could sinusitis be the cure?

AstraZeneca has released data showing its med's effects can last up to two years in severe asthma.